Welcome to our dedicated page for ChronoScale SEC filings (Ticker: EKSO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ChronoScale's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ChronoScale's regulatory disclosures and financial reporting.
Ekso Bionics Holdings, Inc. insider Daniel Asher filed an amended Form 3 updating his beneficial ownership. The filing reports 355,961 shares of Convertible Preferred held indirectly through the Daniel Asher Descendants Trust, 151,663 shares of common stock held indirectly by DBA Trading, LLC, and 165,000 common shares held directly. A footnote clarifies that the DBA Trading, LLC common share balance was corrected from 156,763 to 151,663, and that Asher is deemed to control voting and dispositive power for both the trust and LLC holdings.
Ekso Bionics Holdings insider activity centers on an indirect open-market purchase and updated holdings. An entity associated with major shareholder Daniel Asher, DBA Trading, LLC, bought 1,200 shares of common stock at $9.60 per share, increasing its indirect position to 259,992 common shares. Asher is described as the beneficial owner of DBA Trading, LLC with voting and dispositive control over these shares.
The filing also reports indirect holdings of 355,961 shares of convertible preferred stock through the Daniel Asher Descendants Trust, where Asher is grantor and controls voting and dispositive power, and 165,000 common shares held directly. The preferred and direct common entries are reported as holdings rather than new transactions.
Ekso Bionics Holdings, Inc. ownership update: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 291,146 shares of common stock, representing 9.99% of the class as of 12/31/2025. The filing is an Amendment No. 4 to a Schedule 13G/A and states shared voting and dispositive power over these shares.
The disclosure explains Armistice Capital acts as investment manager to the Armistice Capital Master Fund Ltd., the direct holder; Mr. Boyd is the managing member of Armistice Capital. The Master Fund is identified as having the right to receive dividends or sale proceeds.
Ekso Bionics Holdings, Inc. major shareholder Daniel Asher reported a series of indirect open-market purchases of common stock through DBA Trading, LLC between February 6 and February 13, 2026, at prices around the high-$8 to mid-$9 range per share.
Following these trades, DBA Trading, LLC held 258,792 shares of Ekso Bionics common stock indirectly for Asher, while he also reported 165,000 shares of common stock held directly. In addition, a trust for which Asher is grantor held 2,926 shares of convertible preferred stock, convertible into 355,960 shares of common stock, all reported as indirect beneficial ownership.
Ekso Bionics Holdings, Inc. plans a transformative business combination with Applied Digital’s cloud subsidiary. Ekso will acquire 100% of Applied Digital Cloud Corporation in exchange for issuing 138,216,820 new common shares to APLD’s Contributor entity, which is expected to own about 97% of the combined company’s equity at closing. Ekso will be renamed ChronoScale Corporation and must maintain at least $15,000,000 in cash and cash equivalents, inclusive of PIPE proceeds, for closing. The parties expect the transaction to close in the second calendar quarter of 2026, subject to stockholder approval, regulatory clearances, a PIPE financing and Nasdaq listing approval.
The Second Amended and Restated Articles will increase authorized common shares from 141,428,571 to 290,000,000 and tighten director removal to for-cause only with a 75% voting threshold. A new 2026 Omnibus Equity Incentive Plan will authorize 22,500,000 shares for awards, effective at closing and subject to stockholder approval.
Daniel Asher has filed an initial Form 3 as a 10% owner of Ekso Bionics Holdings, Inc.. He reports beneficial ownership of Ekso common stock and a significant preferred position that can convert into additional common shares.
Asher directly owns 165,000 shares of common stock and indirectly owns 156,763 common shares through DBA Trading, LLC, where he is the beneficial owner with voting and dispositive power. He also indirectly holds Convertible Preferred Stock that is exercisable into 355,961 shares of common stock at a conversion price of $8.22 per share through the Daniel Asher Descendants Trust, where he is the grantor and controls voting and dispositive power.
Ekso Bionics Holdings, Inc. received an amended ownership disclosure showing a significant shareholder position by Daniel Asher. He is reported as beneficial owner of 677,723 ordinary shares, representing 16.51% of the class, with shared voting and dispositive power.
The filing lists related reporting persons including Daniel Asher Descendants Trust, which holds 355,960 shares (8.67%), and DBA Trading, LLC, which holds 156,763 shares (3.82%). The signatories certify the shares are not held for the purpose of changing or influencing control of Ekso Bionics.
Ekso Bionics Holdings, Inc. entered into securities purchase agreements for a private placement of 5,852 shares of newly created Series B Convertible Preferred Stock, each with a stated value of $1,000, convertible into an aggregate of 711,922 shares of common stock at $8.22 per share, and Warrants to purchase up to 355,960 additional common shares at the same exercise price. The transaction closed on January 22, 2026 and is expected to generate approximately $5.3 million in net proceeds, which the company plans to use for working capital and general corporate purposes.
The company also agreed to register the resale of the conversion shares and warrant shares, with a filing deadline of June 1, 2026 and targeted effectiveness within 30–60 days afterward, depending on SEC review. The Series B Preferred Stock carries limited voting rights on an as-converted basis, conversion and warrant exercise caps at 9.99% per holder and 19.99% in the aggregate in certain cases, protective approval rights for key corporate actions, and is redeemable at the stated value at the option of the company or holders starting one year after closing, and upon certain trading failures.
Ekso Bionics Holdings, Inc. received a Schedule 13G reporting a significant ownership position in its ordinary shares. Investor Daniel Asher reports beneficial ownership of 321,763 shares, representing 9.48% of the class, with shared power to vote and dispose of these shares and no sole voting or dispositive power.
Related entity DBA Trading, LLC is identified as a reporting person with shared voting and dispositive power over 156,763 shares and a stated 4.62% of the class. The filing states that Asher is the beneficial owner of DBA Trading, LLC and is deemed to control voting and dispositive power over the shares held by that entity. The certification notes that the securities are not held for the purpose of changing or influencing control of Ekso Bionics.
Ekso Bionics Holdings, Inc. Chief Operating Officer Jason C. Jones reported a sale of company stock in a Form 4 filing. On January 6, 2026, he sold 1,320 shares of common stock at $9.25 per share, with the filing explaining that the sale was made to cover tax withholding obligations from the vesting and settlement of restricted stock awards.
After this transaction, Jones beneficially owned 25,621 shares of Ekso Bionics common stock directly and 3,141 shares indirectly through a 401(k) plan. The filing notes that these share amounts have been adjusted to reflect a 1-for-15 reverse stock split that took effect on June 2, 2025.